COVID‑19 May Boost Antibiotic‑Resistant Bacteria in Nose and Throat, New Study Shows

When most of us think about COVID‑19, the picture that comes to mind is a viral fever, a cough, perhaps a loss of taste. But a fresh look at the microscopic world inside our noses and throats suggests the story might be a bit more tangled. A team of Indian scientists, publishing their findings in Current Microbiology, reported that folks who tested positive for SARS‑CoV‑2 harboured noticeably higher levels of antibiotic‑resistance genes – the genetic tools that turn ordinary bacteria into hard‑to‑kill superbugs.

The researchers collected 95 upper‑respiratory samples from central India and ran shotgun metagenomic sequencing, a mouthful of a technique that essentially reads the DNA of every microbe present. Out of the 22 resistance genes that differed between the COVID‑positive group and healthy volunteers, 21 were more abundant in the infected people. These genes were linked to familiar culprits such as Escherichia coli, Klebsiella pneumoniae and Staphylococcus aureus – bacteria that can cause everything from urinary‑tract infections to life‑threatening sepsis.

It’s important to stress that the virus isn’t magically creating resistance. Rather, the infection appears to reshape the microbial neighbourhood in the upper airway, giving an advantage to bacteria that already carry resistance genes. As Dr. Krishna Khairnar of CSIR‑NEERI put it, the “resistome” – the whole collection of resistance genes – is altered during COVID‑19, enriching it with traits that help bacteria survive antibiotics.

Why does this matter? Secondary bacterial infections have long been a major complication of viral illnesses, and they’re often the reason patients need antibiotics in the first place. If the resident bacteria are already armed with resistance, the usual drug regimens may falter, pushing clinicians toward stronger, broader‑spectrum antibiotics – a step that can fuel the global antimicrobial‑resistance (AMR) crisis.

Some experts urge caution in interpreting the results. Dr. Rajeev Jayadevan notes that the study didn’t track prior antibiotic use, which can also boost resistance genes. He adds that similar shifts have been observed with other respiratory viruses, so the effect may not be exclusive to COVID‑19. Still, the work adds a valuable early‑warning signal: viral infections can tip the delicate balance of our normal flora toward a more resistant state.

India already faces a daunting AMR burden – a 2021 estimate put the number of Indians infected with drug‑resistant bacteria at about 1.07 million, with tens of thousands of deaths attributed to resistant infections. Mapping the resistome in COVID‑19 patients, as this study does, could help public‑health planners fine‑tune surveillance and antibiotic‑stewardship programmes, hopefully keeping the rise of superbugs in check.